MI/26/22 Senior Scientific Officer

Key Details

Job ID:
MI/26/22
Role:
Senior Scientific Officer
Salary:
£28,344 – £45,357 per annum, dependent upon experience
Closing date:
26th July 2026

About the role

We are currently looking for a Senior Scientific Officer (MI3) within Myeloid Cancer Biology Research group at the Cancer Research UK Manchester Institute (University of Manchester). The aim of this post is to support the group’s research into myeloid malignancies (including AML and MDS) contributing to the development and running of patient-relevant experimental models aligned to the lab’s genome-editing and disease-modelling strategy; and progressing projects through rigorous data generation, troubleshooting and clear communication of findings. The group uses genome-editing approaches across mouse platforms and primary patient samples/models to understand disease evolution and identify therapeutic vulnerabilities.

About you

You should have a BSc (or equivalent) in Biological/Biomedical Sciences (or related subject) or equivalent relevant laboratory experience along with extensive practical research lab experience, including mammalian cell culture (ideally primary cells) and experience supporting murine/in vivo models. A current or previous holder of a Personal Licence under the Animals (Scientific Procedures) Act 1986 (PIL A-B) is desirable. You will bring excellent record-keeping and a rigorous approach to data integrity, strong problem-solving and troubleshooting skills, and the ability to contribute to experimental design and interpretation as appropriate.

Headshot photo of Institute Fellow Justin Loke
Paterson Building Scientific Administration

More information

Justin Loke

Justin Loke is a clinician scientist and Institute Fellow at the CRUK Manchester Institute, where he is establishing his new group Myeloid Cancer Biology. He is a Consultant Haematologist at the Christie NHS Foundation Trust. His specialist interest is in the myeloid blood cancers including acute myeloid leukaemia (AML).

Myeloid Cancer Biology Group

Blood cancers often arise from mutations in genes that control normal stem cell development. Disorders originating in the bone marrow, such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), provide valuable systems to study this process.

These diseases typically develop through the accumulation of multiple mutations in haematopoietic stem cells (HSCs), which give malignant cells a growth advantage over healthy ones. Over time, one dominant clone emerges, driving bone marrow failure and severe complications.

What remains poorly understood is how different mutations interact during cancer evolution and how these interactions shape disease behaviour.

Our lab uses advanced genetic editing techniques to build experimental models that more closely mimic the complex mutational landscapes seen in patients.

These models will help us uncover new biological insights and identify novel vulnerabilities that could guide the development of future therapies.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. rnThe Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Justin Loke
Myeloid Cancer Biology Group
About CRUK Manchester Institute

How to apply

To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of two referees and ensure you submit your application before the closing date specified. Informal enquiries can be made to Justin Loke via email justin.loke@cruk.manchester.ac.uk

Closing date: 26 July 2026 Sunday.

Please note this vacancy will close for applications at 18:00 hours on the closing date specified.

Contact us for further information

Enter your full name
Enter your email address
Type your question here

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Images of stained cells superimposed with headshot images of Samra Turajlic and Tim Somervaille
Image of skin cancer in ageing humans

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Two Institute Scientists elected to the Academy of Medical Sciences

We celebrate the recognition Professor Samra Turajlic and Professor Tim Somervaille by a prestigious medical science institution

New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion

Research explores the role of lipid signalling in cancer behaviour

Cancer Research In the Paterson Building
Two Institute Scientists elected to the Academy of Medical Sciences
New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion